Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report), boosting the price target to $44.00.
Rami Katkhuda’s rating is based on several compelling factors surrounding Mineralys Therapeutics, Inc. The analyst highlights the promising results from the pivotal studies, Advance-HTN and Launch-HTN, which have generated excitement among key opinion leaders (KOLs). These studies are particularly significant as they are designed to reflect real-world conditions, providing a more accurate assessment of the drug’s potential impact.
Additionally, the safety profile of lorundrostat, despite some concerns about hyperkalemia, is considered manageable, especially when contextualized with the background regimen used in the studies. The KOL feedback suggests that lorundrostat could address unmet needs in the treatment of resistant hypertension, potentially positioning it as a preferred option over existing treatments like spironolactone. This feedback, combined with the drug’s potential to be used in earlier treatment lines, has led to an increased probability of success for lorundrostat, justifying the Buy rating.
In another report released on March 13, Bank of America Securities also maintained a Buy rating on the stock with a $38.00 price target.